AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Recruiting now · Phase 1/Phase 2

Conditions studied: Metastatic Castration Resistant Prostate Cancer (mCRPC)

In brief

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Key facts

Study ID

NCT07285694

Run by

Arsenal Biosciences, Inc.

People needed

190

Starts

2026-01-09

Expected to finish

2031-05-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States (enrolling)
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado, United States (enrolling)
• University of Iowa and Holden Comprehensive Cancer Center — Iowa City, Iowa, United States (enrolling)
• The University of Kansas Cancer Center — Fairway, Kansas, United States (enrolling)
• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
• Perlmutter Cancer Center - NYU Langone Health — New York, New York, United States (enrolling)
• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.